Oncology Institute (NASDAQ: TOI) grows Q1 revenue 41% and boosts 2026 cash outlook
Rhea-AI Filing Summary
The Oncology Institute, Inc. reported strong first-quarter 2026 results with total operating revenue of $147.4 million, a 41% increase from the prior-year quarter, driven by capitated revenue growth and record performance in its pharmacy business.
Net loss narrowed sharply to $2.5 million from $19.6 million, and Adjusted EBITDA improved to negative $2.4 million from negative $5.1 million. Free Cash Flow was negative $2.4 million, better than negative $4.0 million a year earlier. Cash and cash equivalents were $30.3 million as of March 31, 2026.
For full-year 2026, the company reaffirmed guidance for revenue of $630–$650 million, gross profit of $97–$107 million, and Adjusted EBITDA of $0–$9 million, while raising Free Cash Flow guidance to $5–$15 million. It expects about $150 million in capitated revenue in 2026 and Q2 2026 Adjusted EBITDA between negative $1 million and positive $1 million.
Positive
- Rapid top-line growth and better cash outlook: Q1 2026 operating revenue rose 41% year over year to $147.4 million, net loss narrowed to $2.5 million from $19.6 million, and 2026 Free Cash Flow guidance was raised from $(15)–$5 million to $5–$15 million.
Negative
- Continuing losses and negative equity: Despite improvement, the company still posted a Q1 2026 net loss of $2.5 million, negative Adjusted EBITDA of $2.4 million, and a stockholders’ deficit of $16.3 million as of March 31, 2026.
Insights
Q1 2026 showed rapid growth, sharply lower losses, and a stronger cash outlook.
The Oncology Institute grew Q1 2026 operating revenue to $147.4M, a 41% increase versus Q1 2025, led by capitated contracts and pharmacy volume. Net loss fell to $2.5M from $19.6M, helped by lower interest expense and favorable derivative fair-value movements.
Operationally, Free Cash Flow improved to negative $2.4M from negative $4.0M, and Adjusted EBITDA improved to negative $2.4M from negative $5.1M. Cash stood at $30.3M, while long-term debt was $78.6M, and stockholders’ equity remained negative at $(16.3)M.
For 2026, management reaffirmed revenue guidance of $630–$650M and Adjusted EBITDA of $0–$9M, while raising Free Cash Flow guidance to $5–$15M and targeting about $150M in capitated revenue. They also expect Q2 2026 Adjusted EBITDA between negative $1M and positive $1M. Actual outcomes will depend on capitated lives, costs, and other factors cited in risk disclosures.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
Free Cash Flow financial
capitated revenue financial
value-based contracts financial
derivative warrant liabilities financial
conversion option derivative liabilities financial
Earnings Snapshot
For 2026, revenue $630–$650M, gross profit $97–$107M, Adjusted EBITDA $0–$9M, Free Cash Flow $5–$15M, and expected capitated revenue of about $150M; Q2 2026 Adjusted EBITDA expected between $(1)M and $1M.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
Form
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area
code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.
Item 2.02. Results of Operations and Financial Condition
On May 7, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein.
The information contained in Item 2.02 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release issued by The Oncology Institute, Inc. on May 7, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 7, 2026 | THE ONCOLOGY INSTITUTE, INC. | |
| By: | /s/ Robert Carter | |
| Name: | Robert Carter | |
| Title: | Chief Financial Officer | |
Exhibit 99.1
FOR IMMEDIATE RELEASE
The Oncology Institute Reports First Quarter 2026 Financial Results
CERRITOS, Calif., May 7, 2026 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026.
Recent Operational Highlights
| • | Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 78% in the quarter as compared to prior year same quarter, reflecting the volume growth across our membership and continued attachment rate improvements. |
| • | Contract expansion bringing our total Medicare Advantage lives to 200,000 across 25 counties in Florida effective July 1, 2026. |
| • | Preparing to launch our proprietary provider portal which is designed to strengthen provider engagement and drive continued adherence to our clinical pathways - particularly for our network physicians. |
| • | In connection with our clinical model, we saved approximately $2 million in Medicare spending as part of the CMS Enhancing Oncology Model performance program in period 3 - increasing the savings generated from the previous period while maintaining high-quality care. |
First Quarter 2026 Financial Highlights
All comparisons are to the quarter ended March 31, 2025 unless otherwise noted
| • | Consolidated revenue of $147.4 million increased 41.2% from $104.4 million |
| • | Gross profit of $23.3 million, increased 35.2% |
| • | Net loss of $2.5 million compared to net loss of $19.6 million |
| • | Basic and diluted (loss) earnings per share of $(0.02) compared to $(0.21) |
| • | Adjusted EBITDA of $(2.4) million compared to $(5.1) million |
| • | Cash and cash equivalents of $30.3 million as of March 31, 2026 |
Management Commentary
Daniel Virnich, CEO of TOI, commented, "The first quarter of 2026 was a strong start to the year for TOI, delivering 41% year over year revenue growth, driven in part by strong capitated revenue growth and a record performance in our pharmacy business. We made meaningful progress on several fronts, including in Florida, where we reached profitability, marking an important milestone that reflects the maturation of our capitated relationships in the state, which is a proof point of our model. Our provider portal, which is designed to underscore our commitment to high quality patient care, strengthen provider engagement, and drive continued adherence to our clinical pathways and quality metrics, is preparing for launch this summer. Looking ahead, we are focused on building on the momentum we have coming out of this quarter, are reaffirming our guidance for 2026 revenue and adjusted EBITDA, and feel confident in our ability to execute sustainable profitability over the long term."
Outlook for Fiscal Year 2026
TOI uses Adjusted EBITDA and Free Cash flow, each a non-GAAP metric, as an additional tool to assess its operational and financial performance. See "Financial Information: Non-GAAP Financial Measures" below. In reliance on the unreasonable efforts exception provided under Regulation S-K, TOI is not reasonably able to provide a quantitative reconciliation for forward-looking information of Adjusted EBITDA and Free Cash flow to net (loss) income and net cash provided by operations, respectively, the most directly comparable GAAP financial measures, without unreasonable efforts due to uncertainties regarding capitated lives, direct costs, taxes, capital expenditures, share-based compensation, change in fair value of liabilities, unrealized (gains) losses on investments, consulting and legal fees, transaction costs and other non-cash items. The variability of these items could have an unpredictable, and potentially significant, impact on TOI’s future GAAP financial results.
| 2026 Guidance - Previous | 2026 Guidance - Updated | |||
| Revenue | $630 to $650 million | Unchanged | ||
| Gross Profit | $97 to $107 million | Unchanged | ||
| Adjusted EBITDA | $0 to $9 million | Unchanged | ||
| Free Cash Flow | $(15) to $5 million | $5 to $15 million |
The Company expects approximately $150 million in capitated revenue in 2026. For the second quarter of 2026, we anticipate Adjusted EBITDA of $(1) million to $1 million, reflecting seasonal improvement as deductibles are satisfied and continued ramp of our Florida delegated lives TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating or economic environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings. TOI's outlook assumes a largely stable global market, which would likely be negatively impacted if recent tariff rate increases and exchange rate changes persist and adversely affect world trade.
Webcast and Conference Call
TOI will host a conference call on Thursday, May 7, 2026 at 5:30 p.m. (Eastern Time) to discuss first quarter results and management’s outlook for future financial and operational performance.
The conference call can be accessed live over the phone by dialing 1-800-225-9448, or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 11161701. The replay will be available until Thursday, May 21, 2026.
.
About The Oncology Institute, Inc.
Founded in 2007, The Oncology Institute, Inc. (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 2.0 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “preliminary,” “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “predict,” “potential,” “guidance,” “approximately,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, anticipated financial results, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of TOI and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by anyone as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of TOI. These forward-looking statements are subject to a number of risks and uncertainties, including the accuracy of the assumptions underlying the 2026 full fiscal year outlook and the Q2 2026 outlook with respect to Adjusted EBITDA discussed herein, the outcome of judicial and administrative proceedings to which TOI may become a party or investigations to which TOI may become or is subject that could interrupt or limit TOI’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in TOI’s patient or payors' preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet stock exchange listing standards; the impact of a cybersecurity incident affecting a software provider on TOI’s business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC, including the Item 1A. "Risk Factors" section of TOI's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 12, 2026 and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that TOI currently is evaluating or does not presently know or that TOI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect TOI’s plans or forecasts of future events and views as of the date of this press release. TOI anticipates that subsequent events and developments will cause TOI’s assessments to change. TOI does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing TOI’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Financial Information; Non-GAAP Financial Measures
Some of the financial information and data contained in this press release, such as Adjusted EBITDA and Free Cash Flow, have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). TOI’s non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this press release in conjunction with TOI’s financial statements and the related notes thereto.
TOI believes that the use of Free Cash Flow provides an additional tool to assess the Company's financial performance, evaluate its ability to generate cash from operations, and plan for future investments and obligations. Free Cash Flow is useful in understanding the cash available for strategic initiatives. It also helps in comparing TOI's financial performance with other similar companies, many of which use similar non-GAAP financial measures to provide insights into their cash generation capabilities. However, the principal limitation of Free Cash Flow is that it does not account for certain cash outflows or inflows that are required by GAAP to be recorded in TOI's financial statements. TOI defines Free Cash Flow as net cash flow provided by (used in) operations plus cash paid for interest, less capital expenditures.
TOI believes that the use of Adjusted EBITDA provides an additional tool to assess our operations and results of our performance, to plan and forecast future periods, and factors and trends in, and in comparing our financial measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in TOI's financial statements.
TOI defines Adjusted EBITDA as net (loss) income plus depreciation, amortization, interest, taxes, non-cash items, share-based compensation, goodwill impairment charges, change in fair value of liabilities, unrealized gains or losses on investments and other adjustments to add-back the following: consulting and legal fees related to acquisitions, one-time consulting and legal fees related to certain advisory projects, software implementations and debt or equity financings, severance expense and temporary labor and recruiting charges to build out our corporate infrastructure.
A reconciliation of net cash flow used in operations to Free Cash Flow and net loss to Adjusted EBITDA, the most comparable GAAP metrics, is set forth below:
| Free Cash Flow Reconciliation | ||||||||||||||||
| Three Months Ended March 31, | Change | |||||||||||||||
| (dollars in thousands) | 2026 | 2025 | $ | % | ||||||||||||
| Net cash and cash equivalents used in operating activities | $ | (2,215 | ) | $ | (4,988 | ) | $ | 2,773 | 55.6 | % | ||||||
| Cash paid for interest | 888 | 1,290 | (402 | ) | 31.2 | % | ||||||||||
| Purchases of property and equipment | (1,042 | ) | (328 | ) | (714 | ) | (217.7 | )% | ||||||||
| Free Cash Flow | $ | (2,369 | ) | $ | (4,026 | ) | $ | 1,657 | 41.2 | % | ||||||
| Adjusted EBITDA Reconciliation | ||||||||||||||||
| Three Months Ended March 31, | Change | |||||||||||||||
| (dollars in thousands) | 2026 | 2025 | $ | % | ||||||||||||
| Net loss | $ | (2,492 | ) | $ | (19,585 | ) | $ | 17,093 | (87.3 | )% | ||||||
| Depreciation and amortization | 1,616 | 1,784 | (168 | ) | (9.4 | )% | ||||||||||
| Interest expense, net | 1,934 | 5,570 | (3,636 | ) | (65.3 | )% | ||||||||||
| Income tax and other taxes | 43 | — | 43 | — | % | |||||||||||
| Non-cash addbacks | (248 | ) | (163 | ) | (85 | ) | 52.1 | % | ||||||||
| Share-based compensation | 1,686 | 1,458 | 228 | 15.6 | % | |||||||||||
| Changes in fair value of liabilities | (5,164 | ) | 3,352 | (8,516 | ) | (254.1 | )% | |||||||||
| Unrealized loss on investments | — | 6 | (6 | ) | (100.0 | )% | ||||||||||
| Post-combination compensation expense | — | 13 | (13 | ) | (100.0 | )% | ||||||||||
| Consulting fees | 273 | 332 | (59 | ) | (17.8 | )% | ||||||||||
| Infrastructure and workforce costs | (86 | ) | 2,124 | (2,210 | ) | (104.0 | )% | |||||||||
| Adjusted EBITDA | $ | (2,438 | ) | $ | (5,109 | ) | $ | 2,671 | (52.3 | )% | ||||||
| Key Business Metrics | ||||||||
| Three Months Ended March 31, | ||||||||
| (dollars in thousands) | 2026 | 2025 | ||||||
| Affiliated and Network Clinics (1) | 155 | 81 | ||||||
| Markets | 17 | 18 | ||||||
| Lives under value-based contracts (millions) | 2.0 | 2.0 | ||||||
| Net loss | $ | (2,492 | ) | $ | (19,585 | ) | ||
| Adjusted EBITDA (in thousands) | $ | (2,438 | ) | $ | (5,109 | ) | ||
| (1) | Clinics operated under the TOI PCs, whereby we receive a percentage of revenue under our management services agreements, or MSAs, and are consolidated. Additionally, includes independent oncology practices to which we provide limited management services and have network provider agreements, but do not bear the operating costs. |
Consolidated Balance Sheets (Unaudited)
(in thousands except share data)
| March 31, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 30,280 | $ | 33,565 | ||||
| Accounts receivable, net | 58,134 | 58,998 | ||||||
| Other receivables | 1,316 | 322 | ||||||
| Inventories | 24,290 | 16,875 | ||||||
| Prepaid expenses and other current assets | 2,843 | 2,987 | ||||||
| Total current assets | 116,863 | 112,747 | ||||||
| Property and equipment, net | 10,697 | 10,684 | ||||||
| Operating right of use assets | 22,520 | 22,374 | ||||||
| Intangible assets, net | 10,300 | 11,015 | ||||||
| Goodwill | 7,230 | 7,230 | ||||||
| Other assets | 620 | 606 | ||||||
| Total assets | $ | 168,230 | $ | 164,656 | ||||
| Liabilities and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 47,650 | $ | 43,167 | ||||
| Current portion of operating lease liabilities | 7,404 | 7,156 | ||||||
| Accrued expenses and other current liabilities | 24,297 | 20,639 | ||||||
| Total current liabilities | 79,351 | 70,962 | ||||||
| Operating lease liabilities | 18,843 | 19,131 | ||||||
| Derivative warrant liabilities | 96 | 264 | ||||||
| Conversion option derivative liabilities | 7,595 | 12,591 | ||||||
| Long-term debt, net of unamortized debt issuance costs | 78,611 | 77,400 | ||||||
| Other non-current liabilities | 19 | 28 | ||||||
| Total liabilities | 184,515 | 180,376 | ||||||
| Stockholders’ deficit: | ||||||||
| Common Stock, 0.0001 par value, authorized 500,000,000 shares; 101,707,558 and 99,973,784 shares issued and outstanding at March 31, 2026 and 100,596,918 shares issued and 98,863,144 shares outstanding at December 31, 2025 | 10 | 10 | ||||||
| Series A Convertible Preferred Stock, 0.0001 par value, authorized 10,000,000 shares; 193,507 shares issued and outstanding at March 31, 2026 and 193,507 shares issued and outstanding at December 31, 2025 | — | — | ||||||
| Additional paid-in capital | 258,635 | 256,708 | ||||||
| Treasury Stock at cost, 1,733,774 shares at March 31, 2026 and December 31, 2025 | (1,019 | ) | (1,019 | ) | ||||
| Accumulated deficit | (273,911 | ) | (271,419 | ) | ||||
| Total stockholders’ equity (deficit) | (16,285 | ) | (15,720 | ) | ||||
| Total liabilities and stockholders’ equity (deficit) | $ | 168,230 | $ | 164,656 | ||||
Consolidated Statements of Operations (Unaudited)
(in thousands except share data)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | ||||||||
| Patient services | $ | 59,087 | $ | 53,068 | ||||
| Specialty Pharmacy | 87,541 | 49,293 | ||||||
| Clinical trials & other | 813 | 2,045 | ||||||
| Total operating revenue | 147,441 | 104,406 | ||||||
| Operating expenses | ||||||||
| Direct costs – patient services | 53,383 | 47,080 | ||||||
| Direct costs – specialty pharmacy | 70,743 | 39,863 | ||||||
| Direct costs – clinical trials & other | — | 214 | ||||||
| Selling, general and administrative expense | 28,212 | 25,376 | ||||||
| Depreciation and amortization | 1,616 | 1,784 | ||||||
| Total operating expenses | 153,954 | 114,317 | ||||||
| Loss from operations | (6,513 | ) | (9,911 | ) | ||||
| Other non-operating expense (income) | ||||||||
| Interest expense, net | 1,934 | 5,570 | ||||||
| Change in fair value of derivative warrant liabilities | (168 | ) | 43 | |||||
| Change in fair value of conversion option derivative liabilities | (4,996 | ) | 3,309 | |||||
| Other, net | (791 | ) | 752 | |||||
| Total other non-operating expense (income) | (4,021 | ) | 9,674 | |||||
| Loss before provision for income taxes | (2,492 | ) | (19,585 | ) | ||||
| Income taxes | — | — | ||||||
| Net loss | $ | (2,492 | ) | $ | (19,585 | ) | ||
| Net loss attributable to common stockholders, basic and diluted | $ | (2,094 | ) | $ | (16,075 | ) | ||
| Net loss per share attributable to common stockholders: | ||||||||
| Basic | $ | (0.02 | ) | $ | (0.21 | ) | ||
| Diluted | $ | (0.02 | ) | $ | (0.21 | ) | ||
| Weighted-average number of shares outstanding: | ||||||||
| Basic | 101,801,609 | 77,098,825 | ||||||
| Diluted | 101,801,609 | 77,098,825 | ||||||
Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (2,492 | ) | $ | (19,585 | ) | ||
| Adjustments to reconcile net loss to cash and cash equivalents used in operating activities: | ||||||||
| Depreciation and amortization | 1,616 | 1,784 | ||||||
| Amortization of debt issuance costs and debt discount | 1,211 | 4,874 | ||||||
| Share-based compensation | 1,686 | 1,458 | ||||||
| Change in fair value of liability classified warrants | (168 | ) | 43 | |||||
| Change in fair value of liability classified conversion option derivatives | (4,996 | ) | 3,309 | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 864 | (985 | ) | |||||
| Other receivables | (994 | ) | — | |||||
| Inventories | (7,415 | ) | (2,269 | ) | ||||
| Prepaid expenses | 144 | (1,078 | ) | |||||
| Other assets | (14 | ) | (2 | ) | ||||
| Accounts payable | 4,611 | 5,057 | ||||||
| Change in operating leases | (186 | ) | (162 | ) | ||||
| Accrued expenses and other current liabilities | 3,918 | 2,567 | ||||||
| Other non-current liabilities | — | 1 | ||||||
| Net cash and cash equivalents used in operating activities | (2,215 | ) | (4,988 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (1,042 | ) | (328 | ) | ||||
| Proceeds from asset disposition | — | 126 | ||||||
| Net cash and cash equivalents used in investing activities | (1,042 | ) | (202 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from private placement, net of offering costs | — | 15,359 | ||||||
| Proceeds from employee stock purchase plan | 220 | — | ||||||
| Payments made for financing of insurance payments | (260 | ) | (226 | ) | ||||
| Principal payments on long-term debt | — | (20,000 | ) | |||||
| Principal payments on financing leases | (9 | ) | (10 | ) | ||||
| Common stock issued for options exercised | 21 | 137 | ||||||
| Net cash and cash equivalents provided by (used in) financing activities | (28 | ) | (4,740 | ) | ||||
| Net decrease in cash and cash equivalents | (3,285 | ) | (9,930 | ) | ||||
| Cash and cash equivalents at beginning of period | 33,565 | 49,669 | ||||||
| Cash and cash equivalents at end of period | $ | 30,280 | $ | 39,739 | ||||
| Contacts |
Media
The Oncology Institute, Inc.
Daniel Virnich, MD
danielvirnich@theoncologyinstitute.com
(562) 735-3226 x 81125
Investors
ICR Strategic Communications
investors@icrinc.com